← Eichor
Study identifier: NCT06611137 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

Condition: Laryngeal Cancer · Hypopharynx Cancer  ·  Sponsor: Sun Yat-sen University

PhasePhase 2
Planned participants35
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx

This description comes directly from the study's public registry record.

Talk to the study team

Fang-Yun Xie  ·  +8613902205880  ·  xiefy@sysucc.org.cn

Dian OuYang  ·  ouyd@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06611137